Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zynaxis surprise victim of Lilly cuts

Zynaxis surprise victim of Lilly cuts

Zynaxis Inc. has became the latest company to come under the ax as Eli Lilly and Co. continues to reevaluate its collaborative programs.

Lilly gave notice that it

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE